Mdma

EMD Doses First Patient in MDMA Clinical Trial

Next Investors Oct 09, 2023

Today, our biotech Investment, Emryia (ASX: EMD) has successfully dosed its first patient in a Phase 2b trial using MDMA for the treatment of Post Traumatic Stress Disorder (PTSD).